Jupiter Neurosciences, Inc.
JUNS
$5.24
-$0.76-12.67%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 136.95% | 324.34% | 318.31% | 122.08% | 9.49% |
| Gross Profit | -132.25% | -319.91% | -318.31% | -122.08% | -9.49% |
| SG&A Expenses | 130.19% | 164.39% | 227.95% | 74.91% | 22.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 131.64% | 189.98% | 250.43% | 85.31% | 19.65% |
| Operating Income | -130.64% | -189.27% | -250.43% | -85.31% | -19.65% |
| Income Before Tax | -175.25% | -254.36% | -466.30% | -133.70% | 9.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -175.25% | -254.36% | -466.30% | -133.70% | 9.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -175.25% | -254.36% | -466.30% | -133.70% | 9.16% |
| EBIT | -130.64% | -189.27% | -250.43% | -85.31% | -19.65% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -155.63% | -211.65% | -380.33% | -88.96% | 26.49% |
| Normalized Basic EPS | -100.72% | -126.77% | -169.71% | -44.06% | -1.21% |
| EPS Diluted | -154.59% | -209.36% | -338.00% | -76.61% | 28.82% |
| Normalized Diluted EPS | -104.38% | -131.69% | -177.65% | -46.90% | 0.61% |
| Average Basic Shares Outstanding | 14.03% | 18.61% | 18.29% | 20.67% | 16.63% |
| Average Diluted Shares Outstanding | 11.27% | 15.59% | 15.14% | 17.32% | 19.52% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |